{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:28:39Z","timestamp":1793726919072,"version":"4.6.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> To prospectively investigate the efficacy and tolerance of low-dose rituximab (RTX) for the treatment of neuromyelitis optica-associated optic neuritis (NMO-ON).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Optic Neuritis patients with seropositive aquaporin 4-antibody (AQP4-Ab) were diagnosed with NMO-ON and recruited for treatment with low-dose RTX (100 mg <jats:sup>*<\/jats:sup> 4 infusions) and were then followed monthly for a minimum of 3 months. Reinfusion of 100 mg RTX was given when the CD19+ B lymphocyte frequency was elevated to above 1%. The serum AQP4-Ab level was tested by an enzyme-linked immunosorbent assay (ELISA).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 43 NMO-ON patients (1 male\/42 female, 75 involved eyes) were included in this study. CD19+ B cell clearance in the peripheral blood was induced in 97.7% of patients after induction treatment. A significant decrease in serum AQP4-Ab concentration was observed after induction treatment (<jats:italic>P<\/jats:italic> = 0.0123). The maintenance time of B cell clearance was 5.2 \u00b1 2.25 months. The relapse-free rate was 92.3% in patients followed-up for over 12 months, and patients with non-organ-specific autoimmune antibodies tended to relapse within 6 months. A total of 96.2% of patients had stable or improved vision, and a decrease in the average expanded disability status scale (EDSS) score was found. Structural alterations revealed by optic coherence tomography were observed in both ON and unaffected eyes. The rates of infusion-related reactions and long-term adverse events (AEs) were 18.6 and 23.1%, respectively. No severe AEs was observed.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Low-dose rituximab is efficient and well-tolerated in treating NMO-ON.<\/jats:p>","DOI":"10.3389\/fneur.2021.637932","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T05:09:12Z","timestamp":1620104952000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis"],"prefix":"10.3389","volume":"12","author":[{"given":"Shuo","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanfen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quangang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s00415-016-8155-7","article-title":"Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages","volume":"263","author":"Zhou","year":"2016","journal-title":"J Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e918","DOI":"10.1212\/NXI.0000000000000918","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: part 1","volume":"8","author":"Graf","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00415-018-8771-5","article-title":"Francophone society of multiple S, investigators O: treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study","volume":"265","author":"Cabre","year":"2018","journal-title":"J Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Zephir","year":"2015","journal-title":"J Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"","journal-title":"J Neurol Sci. ("},{"key":"B15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","article-title":"Anti-rituximab antibody in patients with NMOSDs treated with low dose rituximab","volume":"316","author":"Li","year":"2018","journal-title":"J Neuroimmunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1352458514538110","article-title":"Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria","volume":"21","author":"Schippling","year":"2015","journal-title":"Mult Scler"},{"key":"B18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jns.2016.11.016","article-title":"Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up","volume":"372","author":"Evangelopoulos","year":"2017","journal-title":"J Neurol Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"540156","DOI":"10.3389\/fneur.2020.540156","article-title":"AQP4-IgG and MOG-IgG related optic neuritis-prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis","volume":"11","author":"Filippatou","year":"2020","journal-title":"Front Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e702","DOI":"10.1212\/NXI.0000000000000702","article-title":"HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population","volume":"7","author":"Bruijstens","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult Scler."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/NXI.0000000000000317","article-title":"Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study","volume":"4","author":"Valentino","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1742-2094-8-146","article-title":"Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders","volume":"8","author":"Lehmann-Horn","year":"2011","journal-title":"J Neuroinflamm"},{"key":"B29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J Neurol Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jocn.2015.08.033","article-title":"Rapid exacerbation of neuromyelitis optica after rituximab treatment","volume":"26","author":"Dai","year":"","journal-title":"J Clin Neurosci. ("},{"key":"B31","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","article-title":"Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study","volume":"373","author":"Cohen","year":"2017","journal-title":"J Neurol Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"102175","DOI":"10.1016\/j.msard.2020.102175","article-title":"Precision therapy for neuromyelitis optica spectrum disorder: a retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules","volume":"43","author":"Trewin","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jns.2014.11.020","article-title":"Presence of anti-Ro\/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder","volume":"348","author":"Park","year":"2015","journal-title":"J Neurol Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/ene.12714","article-title":"Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica","volume":"23","author":"Masuda","year":"","journal-title":"Eur J Neurol. ("},{"key":"B37","doi-asserted-by":"publisher","first-page":"e805","DOI":"10.1212\/NXI.0000000000000805","article-title":"Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders","volume":"7","author":"Motamedi","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"","journal-title":"Lancet Neurol. ("},{"key":"B39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jns.2017.11.017","article-title":"High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status","volume":"384","author":"Bertsch-Gout","year":"","journal-title":"J Neurol Sci. ("},{"key":"B40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2017.10.001","article-title":"Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica","volume":"313","author":"Akaishi","year":"","journal-title":"J Neuroimmunol. ("}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.637932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T05:09:14Z","timestamp":1620104954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.637932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":40,"alternative-id":["10.3389\/fneur.2021.637932"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.637932","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"article-number":"637932"}}